[High-dose melphalan in patients with multiple myeloma].
Since 1983 an increasing number of clinical trials have used high-dose melphalan with or without autologous stem cell support in patients with multiple myeloma. It has been shown that high-dose therapy including high-dose melphalan may be considered as the treatment of choice in newly diagnosed patients. The purpose of this report is to review and summarize the clinical information on IV high-dose melphalan in patients with multiple myeloma and to examine potential areas of future investigation.
Moreau
P
P
Service d'hématologie clinique, CHU Hôtel-Dieu, place Alexis-Ricordeau, 44093 Nantes.
Le Bonniec
M
M
Harousseau
J L
JL
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007275:Injections, Intravenous; D008558:Melphalan / Q000008:administration & dosage*; D009101:Multiple Myeloma / Q000188:drug therapy / Q000628:therapy*; D019172:Transplantation Conditioning
D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan